Infertility

Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity.

The company has received FDA approval for two products: Cumulase(TM), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex(TM), for use as an adjuvant to increase the absorption and dispersion of other injected drugs.

The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.

Halozyme Contact Investor Relations Contacts David A.

Ramsay Zachary Bryant Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8889 (310) 691-7100 dramsay@halozyme.com zbryant@lhai.com CONTACT: David A.

Ramsay, Chief Financial Officer of HalozymeTherapeutics, Inc., +1-858-794-8889, ; or InvestorRelations, Zachary Bryant of Lippert/Heilshorn & Associates,+1-310-691-7100, , for Halozyme Therapeutics, Inc.

dramsay@halozyme.com zbryant@lhai.com Web site: http://www.halozyme.com/ Ticker Symbol: (AMEX:HTI) Terms and conditions of use applyCopyright © 2006 PR Newswire Association LLC.

All rights reserved.A United Business Media Co...

Read more...